Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Non-Hodgkin Lymphoma Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Non-Hodgkin Lymphoma Therapeuticsmarket, defines the market attractiveness level of Non-Hodgkin Lymphoma Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Non-Hodgkin Lymphoma Therapeutics industry, describes the types of Non-Hodgkin Lymphoma Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Non-Hodgkin Lymphoma Therapeutics market and the development prospects and opportunities of Non-Hodgkin Lymphoma Therapeutics industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Non-Hodgkin Lymphoma Therapeutics market in Chapter 13.
By Player:
GlaxoSmithKline
Eisai Pharmaceuticals
Cephalon
Eli Lilly
Bayer
F Hoffman La-Roche
Bristol Myers Squibb
Baxter International
Accredo Health Group
Celgene
By Type:
Chemotherapy
Targeted Therapy
By End-User:
Clinical Research
Treatment
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Non-Hodgkin Lymphoma Therapeutics Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Non-Hodgkin Lymphoma Therapeutics Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Non-Hodgkin Lymphoma Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Non-Hodgkin Lymphoma Therapeutics Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Non-Hodgkin Lymphoma Therapeutics Market Analysis and Outlook to 2022
-
7.1 Global Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
-
7.2 United States Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
-
7.3 Europe Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
-
7.4 China Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
-
7.5 Japan Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
-
7.6 India Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
-
7.7 South Korea Non-Hodgkin Lymphoma Therapeutics Consumption (2017-2022)
8 Region and Country-wise Non-Hodgkin Lymphoma Therapeutics Market Analysis and Outlook to 2028
-
8.1 Global Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
-
8.2 United States Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
-
8.3 Europe Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
-
8.4 China Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
-
8.5 Japan Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
-
8.6 India Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
-
8.7 South Korea Non-Hodgkin Lymphoma Therapeutics Consumption Forecast (2022-2028)
9 Global Non-Hodgkin Lymphoma Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Targeted Therapy Consumption and Growth Rate (2017-2022)
-
9.2 Global Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Clinical Research Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Treatment Consumption and Growth Rate (2017-2022)
10 Global Non-Hodgkin Lymphoma Therapeutics Market Outlook by Types and Applications to 2028
-
10.1 Global Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Clinical Research Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Treatment Consumption Forecast and Growth Rate (2022-2028)
11 Global Non-Hodgkin Lymphoma Therapeutics Import and Export Analysis (Top 5 Countries)
-
11.1 Global Non-Hodgkin Lymphoma Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Non-Hodgkin Lymphoma Therapeutics Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Non-Hodgkin Lymphoma Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Non-Hodgkin Lymphoma Therapeutics Market Competitive Analysis
-
14.1 GlaxoSmithKline
-
14.1.1 GlaxoSmithKline Company Details
-
14.1.2 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.2 Eisai Pharmaceuticals
-
14.2.1 Eisai Pharmaceuticals Company Details
-
14.2.2 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.3 Cephalon
-
14.3.1 Cephalon Company Details
-
14.3.2 Cephalon Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Cephalon Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.4 Eli Lilly
-
14.4.1 Eli Lilly Company Details
-
14.4.2 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.5 Bayer
-
14.5.1 Bayer Company Details
-
14.5.2 Bayer Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Bayer Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.6 F Hoffman La-Roche
-
14.6.1 F Hoffman La-Roche Company Details
-
14.6.2 F Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 F Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.7 Bristol Myers Squibb
-
14.7.1 Bristol Myers Squibb Company Details
-
14.7.2 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.8 Baxter International
-
14.8.1 Baxter International Company Details
-
14.8.2 Baxter International Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Baxter International Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.9 Accredo Health Group
-
14.9.1 Accredo Health Group Company Details
-
14.9.2 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Product and Service
-
14.10 Celgene
-
14.10.1 Celgene Company Details
-
14.10.2 Celgene Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Celgene Non-Hodgkin Lymphoma Therapeutics Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Non-Hodgkin Lymphoma Therapeutics
-
Figure Non-Hodgkin Lymphoma Therapeutics Picture
-
Table Global Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Non-Hodgkin Lymphoma Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Non-Hodgkin Lymphoma Therapeutics Consumption by Country (2017-2022)
-
Figure United States Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure China Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Non-Hodgkin Lymphoma Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Hodgkin Lymphoma Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Non-Hodgkin Lymphoma Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Clinical Research Consumption and Growth Rate (2017-2022)
-
Figure Global Treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinical Research Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Non-Hodgkin Lymphoma Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Non-Hodgkin Lymphoma Therapeutics Export by Region (Top 5 Countries) (2017-2028)
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Eisai Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Cephalon (Foundation Year, Company Profile and etc.)
-
Table Cephalon Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cephalon Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Bayer (Foundation Year, Company Profile and etc.)
-
Table Bayer Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table F Hoffman La-Roche (Foundation Year, Company Profile and etc.)
-
Table F Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Bristol Myers Squibb (Foundation Year, Company Profile and etc.)
-
Table Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Baxter International (Foundation Year, Company Profile and etc.)
-
Table Baxter International Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Baxter International Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Accredo Health Group (Foundation Year, Company Profile and etc.)
-
Table Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Product and Service
-
Table Celgene (Foundation Year, Company Profile and etc.)
-
Table Celgene Non-Hodgkin Lymphoma Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Non-Hodgkin Lymphoma Therapeutics Product and Service
-
